Provided by Tiger Trade Technology Pte. Ltd.

Foghorn Therapeutics Inc.

4.93
+0.13002.71%
Post-market: 4.930.00000.00%17:45 EDT
Volume:122.42K
Turnover:608.72K
Market Cap:288.81M
PE:-4.18
High:5.10
Open:4.88
Low:4.88
Close:4.80
52wk High:6.95
52wk Low:2.94
Shares:58.58M
Float Shares:28.87M
Volume Ratio:0.53
T/O Rate:0.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1800
EPS(LYR):-1.1800
ROE:-470.38%
ROA:-21.29%
PB:-2.66
PE(LYR):-4.18

Loading ...

Foghorn Therapeutics Price Target Maintained With a $10.00/Share by Wedbush

Dow Jones
·
Mar 12

Foghorn Therapeutics (FHTX) Receives a Buy from Guggenheim

TIPRANKS
·
Mar 12

Buy Rating on Foghorn Therapeutics Driven by Lilly Partnership Catalyst, Advancing Degrader Pipeline, and Strengthened Cash Runway

TIPRANKS
·
Mar 12

Foghorn Advances FHD-909 Trial and Strengthens Financial Position

TIPRANKS
·
Mar 12

Foghorn Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 12

Foghorn Therapeutics Q4 EPS $(0.34) Misses $(0.27) Estimate, Sales $9.247M Miss $9.500M Estimate

Benzinga
·
Mar 12

Foghorn Therapeutics FY 2025 collaboration revenues rise 37% to USD 30.9 million, net loss narrows 14% to USD 74.3 million

Reuters
·
Mar 12

Press Release: Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook

Dow Jones
·
Mar 12

Foghorn Therapeutics Price Target Maintained With a $13.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 10

Foghorn Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview

Reuters
·
Mar 07

Foghorn Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview

Reuters
·
Mar 03

Foghorn Therapeutics Files Initial Beneficial Ownership Statement for CFO Ryan D. Maynard

Reuters
·
Feb 25

Foghorn Therapeutics to Present at TD Cowen Annual Health Care Conference and Citizens Life Sciences Conference

Reuters
·
Feb 24

Foghorn Therapeutics Names Veteran Executive as New CFO

TIPRANKS
·
Feb 23

Foghorn Therapeutics appoints Maynard as Chief Financial Officer

TIPRANKS
·
Feb 23

Foghorn Therapeutics Names Ryan Maynard Chief Financial Officer

Reuters
·
Feb 23

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Qiagen (QGEN) and Foghorn Therapeutics (FHTX)

TIPRANKS
·
Feb 18

Foghorn Therapeutics Is Maintained at Buy by Jefferies

Dow Jones
·
Feb 18

Foghorn Therapeutics to Present at Guggenheim Emerging Outlook Biotech Summit

Reuters
·
Feb 03

Press Release: Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium

Dow Jones
·
Jan 14